Psychedelic Therapies Gain Momentum in Canada Canadian psychedelic stocks are gaining attention as companies like Compass Pathways advance psilocybin therapies for depression. With Phase 3 trials underway, the sector shows potential for groundbreaking treatments. However, significant risks remain, including regulatory hurdles and funding challenges, making this an area for cautious investment.2